Founded in 2003, Mason-based Aprecia Pharmaceuticals develops and manufactures medicines using three-dimensional printing, an approach that enables novel oral drug-delivery forms. Aprecia is the first company to secure regulatory approval and commercialize a 3D-printed pharmaceutical product, Spiritam®, which is produced at its cGMP manufacturing facility. The privately held company combines formulation and manufacturing expertise with a portfolio of 126 granted patents and 52 pending patents.
cGMP compliant
compliance_program
FDA inspected and registered facility
registration
FDA Emerging Technology Program
compliance_program